Table 1. Patients and disease characteristics.
| Cohort A | Cohort B | p value | |
|---|---|---|---|
| Age, years | 0.10 | ||
| Median (IQR) | 57 (48–67) | 60.5 (53–71) | |
| Gender, n (%) | 0.38 | ||
| Women | 49 (42) | 47 (37) | |
| Men | 67 (58) | 81 (63) | |
| Primary site, n (%) | 0.18 | ||
| Cutaneous | 90 (78) | 100 (78) | |
| Mucosal | 7 (6) | 11 (9) | |
| Ocular | 5 (4) | 10 (8) | |
| Unknown | 14 (12) | 7 (5) | |
| AJCC stage, n (%) | 0.75 | ||
| 3c + M1a + M1b | 25 (22) | 26 (20) | |
| M1c | 88 (78) | 101 (80) | |
| Not known | 3 | 1 | |
| Serum LDH, n (%) | 0.02 | ||
| < ULN | 65 (61) | 57 (45) | |
| ≥ ULN | 42 (39) | 69 (55) | |
| Not available | 9 | 2 | |
| Previous lines of therapy, n (%) | < 0.0001 | ||
| 0 | 90 (78) | 29 (23) | |
| ≥ 1 | 26 (22) | 99 (77) | |
| LDH-ratio, n (%) | 0.84 | ||
| ≤ 2.5 | 96 (90) | 112 (89) | |
| > 2.5 | 11 (10) | 14 (11) | |
| Pattern of metastasis, n (%) | 0.39 | ||
| Lymph nodes, soft tissues, lung | 33 (28) | 43 (34) | |
| Other visceral | 83 (72) | 85 (66) | |
| Relative lymphocyte count (RLC), n (%) | 0.41 | ||
| < 17.5% | 35 (30) | 45 (35) | |
| ≥ 17.5% | 81 (70) | 83 (65) | |
| Relative eosinophil count (REC), n (%) | 0.41 | ||
| < 1.5% | 61 (53) | 74 (58) | |
| ≥ 1.5% | 55 (47) | 54 (42) |
Cohort A: 116 patients receiving chemotherapy; cohort B: 128 patients receiving anti-CTLA-4. p values are from Mann-Whitney test (age) or chi-square test (all other variables). Abbreviations: AJCC: American Joint Committee on Cancer; IQR: interquartile range; LDH: lactate dehydrogenase; n: number of patients; ULN: upper limit of normal.